Sally Pipes is the Pacific Research Instituteโs president, CEO and Thomas W. Smith Fellow in Health Care policy who analyzes the latest health care trends and topics including single-payer, Obamacare, drug pricing and Medicare. A former Canadian, sheโs written about the health care policies in her native country that would bring harm to U.S. patients if imported across the border. Her latest book is โThe Worldโs Medicine Chestโ (Encounter 2025). She received an honorary PhD from Pepperdine Universityโs School of Public Policy for her work on health care reform. Follow Pipes for continued insight on U.S. health care policy proposals, the dangers of government-run health care, and reforms to provide better quality and access to health care while lowering costs.
Tariffs Wonโt Secure Our Drug Supply ChainโTheyโll Break It
Imposing Section 232 tariffs on medicines would worsen shortages, drive up prices, and leave patients with fewer options.
Generics Must Compete On Price, Not Safety
The FDAโs draft guidance sends the opposite message: that standards can be bent, and safety is negotiable.
The Trump Administration Is Reviving Its Worst Drug Pricing Policies
President Trump wrote to major drug companies, informing them that they had to comply with his โMost Favored Nationโ order.
Drugmakers Are Embracing Direct-To-Consumer Sales. That's Fantastic News For Patients.
As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at fair, transparent prices.
Obamacare Premiums Are Climbing Again. But Americans Finally Have An Alternative.
Obamacare premiums rise every year. But there are two things that make this yearโs premium hikes different.